Eric Springman, Ph.D. Chief Scientific Officer

ATLANTA, GA — December 9, 2009 – Celtaxsys, Inc., a privately held biopharmaceutical company focused on novel mechanisms of inflammation therapy, announced that it has hired Eric B. Springman, Ph.D. to the position of Chief Scientific Officer. In this new role, Dr. Springman will lead Celtaxsys’ research and drug discovery activities, and will serve on the company’s management team.

Before joining Celtaxsys, Dr. Springman was a Senior Director at Locus Pharmaceuticals, where he played a leading role in each of the company’s three IND programs. During his tenure at Locus Dr. Springman was also responsible for founding the Biology Department, integrating Structural Biology into the technology platform, garnering significant grant funding for the company’s research, and revitalizing the company’s Discovery Technologies core. Prior to Locus, Dr. Springman held positions of increasing responsibility at Roche Pharmaceuticals in Palo Alto, CA, including Acting Head of the Arthritis Therapy Area. Prior to that he worked at Arris/Axys Pharmaceuticals where he was co-leader of the partnered project resulting in Merck's Phase III drug candidate, Odanacatib. In 2007, Dr. Springman was appointed by Governor Edward Rendell to the Pennsylvania Drug, Device & Cosmetics Board.

Dr. Springman received a B.A. in Chemistry/Biology from Florida Atlantic University, a Ph.D. in Biophysics from Florida State University, and was an NRSA and American Lung Association Post-Doctoral Fellow in Pharmacology at Vanderbilt University Medical Center. “I am excited to join Celtaxsys and help lead the Company’s efforts to commercialize its platform assets, with particular focus on selecting candidate compounds to move expeditiously into the clinic.” said Dr. Springman.

“We are delighted that Eric is joining us at such an exciting time, as we move into development of our anti-inflammatory compounds,” said Bill Reddick, President of Celtaxsys. “Eric brings a wealth of experience leading drug discovery R&D operations, and his depth of knowledge will be highly valued as our team continues to advance our therapeutic programs”.

CELTAXSYS - THE INNATE IMMUNE COMPANY